Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pariente

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.
Inflammatory Bowel Diseases|June 2, 2017
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel DiseaseAnthony Buisson, Florent Gonzalez, Florian Poullenot, et al.
The American Journal of Gastroenterology|November 6, 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAIDConstance Chapuis-Biron, Julien Kirchgesner, Benjamin Pariente, et al.
Gastroenterology|May 30, 2021
Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn's DiseaseBenjamin Pariente, Joana Torres, Johan Burisch, et al.
Gastroenterology|January 11, 2018
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's DiseaseGeert D'Haens, Severine Vermeire, Guy Lambrecht, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|December 24, 2019
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's diseaseParambir S Dulai, Aurelien Amiot, Laurent Peyrin-Biroulet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 23, 2020
Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID studyThomas Lambin, Aurélien Amiot, Carmen Stefanescu, et al.
Gastroenterology|September 22, 2014
Development of the Lémann index to assess digestive tract damage in patients with Crohn's diseaseBenjamin Pariente, Jean-Yves Mary, Silvio Danese, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.
Inflammatory Bowel Diseases|June 2, 2017
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel DiseaseAnthony Buisson, Florent Gonzalez, Florian Poullenot, et al.
The American Journal of Gastroenterology|November 6, 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAIDConstance Chapuis-Biron, Julien Kirchgesner, Benjamin Pariente, et al.
Gastroenterology|May 30, 2021
Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn's DiseaseBenjamin Pariente, Joana Torres, Johan Burisch, et al.
Gastroenterology|January 11, 2018
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's DiseaseGeert D'Haens, Severine Vermeire, Guy Lambrecht, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|December 24, 2019
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's diseaseParambir S Dulai, Aurelien Amiot, Laurent Peyrin-Biroulet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 23, 2020
Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID studyThomas Lambin, Aurélien Amiot, Carmen Stefanescu, et al.
Gastroenterology|September 22, 2014
Development of the Lémann index to assess digestive tract damage in patients with Crohn's diseaseBenjamin Pariente, Jean-Yves Mary, Silvio Danese, et al.
Pageof 9